Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.19), $0.42 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $58.98 million versus the consensus estimate of $31.21 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.